Why RxSight (RXST) Shares Are Falling
RxSight shares are trading lower by 5.6% during Thursday's session. The company announced pricing of its $100 million proposed public offering of common stock.
RxSight Announces $100M Proposed Public Offering Of Common Stock
RxSight, Inc., (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject
What 10 Analyst Ratings Have To Say About RxSight
Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on RxSight (NASDAQ:RXST)…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Agape ATP (NASDAQ:ATPC) shares rose 23.0% to $0.32 during Monday’s after-market session. The market value of their…
Assessing RxSight: Insights From 8 Financial Analysts
RxSight (NASDAQ:RXST) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish…
The Analyst Landscape: 8 Takes On RxSight
In the preceding three months, 8 analysts have released ratings for RxSight (NASDAQ:RXST), presenting a wide array of…
Jim Cramer: This Healthcare Stock Is ‘Too Risky,’ But Shares Jumped 64% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is "too risky."
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.
Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
Breaking Down RxSight: 5 Analysts Share Their Views
5 analysts have shared their evaluations of RxSight (NASDAQ:RXST) during the recent three months, expressing a mix of…
RxSight, Inc. Announces Preliminary Unaudited Q4 And FY23 Financial And Operational Results And 2024 Guidance; Sees Q4 Revenue $28.6M Vs $25.76M Est.; Sees FY23 Revenue $89.1M Vs $86.34M Est.; Sees FY24 Revenue $128M-$135M Vs $121.48M Est.
RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational